Electromedical Announces
Addition of David Orn as Director of Business and Sales
Development
Orn to Focus on Expansion of Sales
and Distribution for Wellness Pro Plus Device
SCOTTSDALE, AZ -- March 8, 2022
-- InvestorsHub NewsWire -- Electromedical Technologies, Inc.
(OTC:
EMED) ("Electromedical" or the "Company"), a pioneer in the
development and manufacturing of bioelectronic devices, is excited
to announce that the Company has hired its first Business and Sales
Development Director, David Orn, to drive a material expansion of
sales and strategic distribution channels for Electromedical's
flagship Wellness Pro Plus next-generation therapeutic
device.
"I couldn't be more excited to
join the Electromedical team," stated Mr. Orn. "I see this
opportunity as a way to contribute to an enthusiastic,
forward-thinking, fast-moving company set to revolutionize the
medical device space. I have been consistently impressed by the
culture and leadership at Electromedical. CEO Matthew Wolfson and
CIO Petar Gajic have demonstrated humility, expertise, drive, and
an upbeat attitude that is infectious. I believe that
Bioelectronics and Electroceuticals will have a huge impact on
medicine and the opioid crisis. Electromedical Technologies
is perfectly positioned to address the growing demand for self care
and drug free therapies that help people relieve chronic pain and
improve quality of life. I have been searching for an
opportunity with a company involved in such exciting and innovative
work that makes a positive difference in people's lives. And I feel
confident at this point that I've found it."
David is a veteran in the
medical industry, with prior experience working with teams
including Zimmer Biomet and Medtronic, where he developed and
oversaw marketing functions to identify key strategies for
successful customer acquisition and sales growth. He has also
previously collaborated with business development, marketing &
product development teams in the creation of competitive concept
proposals across various industries.
David has also worked to develop
new service offerings based on detailed and documented insights
related to market and client needs for regional hospitals and
medical groups. His experience includes work to enhance firm market
reputation through improvements to go-to-market strategies as well
as through the creation of new profit centers across multiple
industries.
Matthew Wolfson, CEO of
Electromedical, noted, "David is the perfect addition to our
equation right now. We have low-hanging fruit on the vine and a
great deal of potential in place just waiting to be tapped by
someone with his caliber of experience and talent. We are confident
David will help us achieve our fundamental targets over the coming
year and for years to come, and we welcome him with open arms as we
focus on achieving our fundamental milestones in the quarters
ahead. We have a number of fresh catalysts on tap and we look
forward to providing additional details in coming
communications."
About Electromedical Technologies
Headquartered in Scottsdale,
Arizona, Electromedical Technologies, Inc. is a commercial stage,
FDA cleared, bioelectronic medical device manufacturing company
initially focused on the treatment of various chronic, acute,
intractable, and post-operative pain conditions. Through University
collaboration agreements, the Company is working to develop a
comprehensive research program in defining the effects of
electro-modulation on the human body. By studying the impacts of
electrical fields in cell signaling and effects on virus assembly
and immune responses, the Company's goal is to reduce pain and
improve overall human wellbeing. The Company's current FDA cleared
product indications are for chronic acute post traumatic and
post-operative, intractable pain relief.
For more
information, please visit www.electromedtech.com.
Note: Nonhuman preliminary
studies that we are planning to start in the near future and their
applications are not related to our current product in any way and
are currently not cleared in the US.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance or guarantee that such expectations and assumptions
will prove to have been correct. Forward-looking statements are
generally identifiable by the use of words like "may," "will,"
"should," "could," "expect," "anticipate," "estimate," "believe,"
"intend," or "project" or the negative of these words or other
variations on these words or comparable terminology. The reader is
cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous factors and
uncertainties, including but not limited to: adverse economic
conditions, competition, adverse federal, state and local
government regulation, international governmental regulation,
inadequate capital, inability to carry out research, development
and commercialization plans, loss or retirement of key executives
and other specific risks. To the extent that statements in this
press release are not strictly historical, including statements as
to revenue projections, business strategy, outlook, objectives,
future milestones, plans, intentions, goals, future financial
conditions, events conditioned on stockholder or other approval, or
otherwise as to future events, such statements are forward-looking,
and are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made.
Corporate Contact:
Electromedical
Technologies, Inc.
Tel:
1.888.880.7888
Email:
ir@electromedtech.com
https://electromedtech.com
Public Relations:
EDM Media,
LLC
https://edm.media